: Amyloid-beta (Abeta) is a 39-43 amino acid peptide derived from a large precursor protein known as the amyloid precursor protein (APP). Abundant evidence suggests that the conversion of Abeta from soluble to insoluble forms and its buildup in the brain is a key step in the pathogenesis of Alzheimer's disease (AD). There is a strong likelihood that prevention/reversal of this process may serve as a treatment for AD. Utilization of transgenic (Tg) mouse models of AD which develop age-dependent Abeta deposition have provided useful models to test whether different manipulations can influence this and other AD-related pathology. Recent studies have shown that active immunization in Tg mouse models of AD can decrease Abeta deposition and that passive parenteral administration of certain anti-Abeta antibodies appear to mimic this effect. The mechanism as to how anti-Abeta antibodies result in prevention/reversal of Abeta deposition has not yet been clarified. In exploring factors which alter soluble Abeta clearance, we found that a monoclonal antibody (m266) directed against the central domain of Abeta was able to bind and completely sequester all plasma Abeta in a mouse model of APPV717F Tg mice. Peripheral administration of m266 to APPV717F Tg mice, in which Abeta is generated specifically within the CNS, resulted in a rapid 1000-fold increase in plasma Abeta and altered dynamics of extracellular Abeta metabolism in the CNS. Peripheral administration of m266 to APPV717F Tg mice also markedly reduced Abeta deposition in the brain when administered chronically. Thus, our findings have led us to hypothesize that certain anti-Abeta antibodies alter Abeta clearance and diminish AD pathology in large part by increasing net transport of Abeta from CNS to plasma. We will test this and other ideas in the following Aims:
Aim 1 : We have developed an in vivo assay to measure the net rate of Abeta entering the plasma of APPV717F Tg mice. Utilizing this assay, we will test the hypothesis that the ability of specific anti-Abeta antibodies to result in net """"""""efflux"""""""" of Abeta from CNS to plasma will best correlate with their ability to prevent/reverse Abeta deposition chronically.
Aim 2 : Our preliminary data suggest that the rate of Abeta entry from CNS to plasma is influenced by the presence or absence of Abeta deposits in plaques. We will test this idea in APP V717F 00Tg mice with our in vivo Abeta efflux assay.
Aim 3 : Abeta is transported from CNS to plasma and plasma to CNS across the blood brain barrier. We will use direct methods to determine the effect of anti-Abeta antibodies on bi-directional transport rates of Abeta from brain to plasma and from plasma to brain. This will determine how anti-Abeta antibodies influence CNS/plasma Abeta transport exchanges.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG020222-02
Application #
6533954
Study Section
Special Emphasis Panel (ZAG1-PCR-5 (O4))
Program Officer
Snyder, Stephen D
Project Start
2001-09-30
Project End
2004-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
2
Fiscal Year
2002
Total Cost
$394,500
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Brody, David L; Holtzman, David M (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175-93
Brody, David L; Holtzman, David M (2006) Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp Neurol 197:330-40
Brendza, Robert P; Holtzman, David M (2006) Amyloid-beta immunotherapies in mice and men. Alzheimer Dis Assoc Disord 20:118-23
Deane, Rashid; Sagare, Abhay; Hamm, Katie et al. (2005) IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25:11495-503
Brendza, Robert P; Bacskai, Brian J; Cirrito, John R et al. (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 115:428-33
Legleiter, Justin; Czilli, Dan L; Gitter, Bruce et al. (2004) Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol 335:997-1006
Legleiter, Justin; DeMattos, Ronald B; Holtzman, David M et al. (2004) In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins. J Colloid Interface Sci 278:96-106
Cirrito, John R; May, Patrick C; O'Dell, Mark A et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23:8844-53
Lemere, Cynthia A; Spooner, Edward T; LaFrancois, John et al. (2003) Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 14:10-8
Holtzman, David M; Bales, Kelly R; Paul, Steven M et al. (2002) Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv Drug Deliv Rev 54:1603-13

Showing the most recent 10 out of 12 publications